Literature DB >> 25790744

Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system.

Liesl K Jeffers-Francis1, Raquel Burger-Calderon2, Jennifer Webster-Cyriaque3.   

Abstract

BK polyomavirus (BKPyV) is a known kidney tropic virus that has been detected at high levels in HIV-associated salivary gland disease (HIV-SGD), one of the most important AIDS associated oral lesions. BKPyV has been detected in HIV-SGD patient saliva and replicates in salivary gland cells in vitro. BKPyV antivirals are currently in wide use to guard against BKPyV mediated organ rejection in kidney transplant recipients. The goal of this study was to investigate the inhibitory effects of three such antiviral agents, Ciprofloxacin, Cidofovir, and Leflunomide in BKPyV infected salivary gland cells. Human salivary gland cells, and Vero cells, were infected with BKPyV, treated with antiviral drugs and assessed for BKPyV gene expression and viral replication for up to 5 days post infection. The kinetics of BKPyV replication were different in salivary gland cells compared to kidney cells. Ciprofloxacin and Cidofovir had minimal effect on metabolic activity and host cell DNA replication, however, cell toxicity was detected at the protein level with Leflunomide treatment. Ciprofloxacin decreased BKV T Ag and VP1 mRNA expression by at least 50% in both cell types, and decreased T Ag protein expression at days 3 and 4 post infection. A 2.5-4 log decrease in intracellular DNA replication and a 2-3 log decrease in progeny release were detected with Ciprofloxacin treatment. Cidofovir and Leflunomide also inhibited BKPyV gene expression and DNA replication. The three drugs diminished progeny release by 30-90% and 2- to 6-fold decreases in infectious virus were detected post drug treatment by fluorescence focus assay. Additionally, three clinical BKPyV isolates were assessed for their responses to these agents in vitro. Cidofovir and Leflunomide, but not Ciprofloxacin treatment resulted in statistically significant inhibition of BKPyV progeny release from salivary gland cells infected with HIVSGD BKPyV isolates. All three drugs decreased progeny release from cells infected with a transplant derived viral isolate. In conclusion, treatment of human salivary gland cells with each of the three drugs produced modest decreases in BKPyV genome replication. These data highlight the need for continued studies to discover more effective and less toxic drugs that inhibit BKPyV replication in salivary gland cells.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BKPyV; Cidofovir; Ciprofloxacin; HIV-associated salivary gland disease; Leflunomide; Polyomavirus; Salivary gland cells

Mesh:

Substances:

Year:  2015        PMID: 25790744      PMCID: PMC4424161          DOI: 10.1016/j.antiviral.2015.02.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  49 in total

1.  Clinical uses of cidofovir.

Authors: 
Journal:  Rev Med Virol       Date:  1997-09       Impact factor: 6.989

Review 2.  Viruses and salivary gland disease (SGD): lessons from HIV SGD.

Authors:  L Jeffers; J Y Webster-Cyriaque
Journal:  Adv Dent Res       Date:  2011-04

3.  Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.

Authors:  D Topalis; I Lebeau; M Krecmerová; G Andrei; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

4.  Salivary gland lymphadenopathies associated with AIDS.

Authors:  H L Ioachim; J R Ryan
Journal:  Hum Pathol       Date:  1988-05       Impact factor: 3.466

5.  Lactoferrin inhibits early steps of human BK polyomavirus infection.

Authors:  Giovanna Longhi; Valeria Pietropaolo; Monica Mischitelli; Catia Longhi; Maria Pia Conte; Magda Marchetti; Antonella Tinari; Piera Valenti; Anna Marta Degener; Lucilla Seganti; Fabiana Superti
Journal:  Antiviral Res       Date:  2006-06-02       Impact factor: 5.970

6.  CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes.

Authors:  Rainer Gosert; Christine Hanssen Rinaldo; Marion Wernli; Eugene O Major; Hans H Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

Review 7.  Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance.

Authors:  J A DiGiuseppe; R L Corio; W H Westra
Journal:  Curr Opin Oncol       Date:  1996-05       Impact factor: 3.645

8.  Treatment of renal allograft polyoma BK virus infection with leflunomide.

Authors:  Michelle A Josephson; Daniel Gillen; Basit Javaid; Pradeep Kadambi; Shane Meehan; Preston Foster; Robert Harland; Richard J Thistlethwaite; Marc Garfinkel; Walter Atwood; Joslynn Jordan; Molly Sadhu; Michael J Millis; James Williams
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939

9.  A novel treatment regimen for BK viremia.

Authors:  Rumina A Zaman; Robert B Ettenger; Hay Cheam; Mohammed H Malekzadeh; Eileen W Tsai
Journal:  Transplantation       Date:  2014-06-15       Impact factor: 4.939

10.  Polyomavirus in saliva of HIV-infected children, Brazil.

Authors:  Tatiana F Robaina; Gabriella S Mendes; Fabrício J Benati; Giselle A Pena; Raquel C Silva; Miguel A R Montes; Renata Otero; Gloria F Castro; Fernando P Câmara; Norma Santos
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

View more
  8 in total

Review 1.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

Review 2.  Human BK Polyomavirus-The Potential for Head and Neck Malignancy and Disease.

Authors:  Raquel Burger-Calderon; Jennifer Webster-Cyriaque
Journal:  Cancers (Basel)       Date:  2015-07-08       Impact factor: 6.639

Review 3.  In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection.

Authors:  Heidi Barth; Morgane Solis; Wallys Kack-Kack; Eric Soulier; Aurélie Velay; Samira Fafi-Kremer
Journal:  Viruses       Date:  2016-10-22       Impact factor: 5.048

4.  Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro.

Authors:  Jie Ruan; Shuo Sun; Xin Cheng; Pengyu Han; Yinge Zhang; Dianxing Sun
Journal:  Virol J       Date:  2020-07-01       Impact factor: 4.099

Review 5.  Fluoroquinolones and BK Virus Nephropathy: A Myth or a Reality.

Authors:  M A M Khalil; M A U Khalil; J Tan; T F T Khan
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

Review 6.  Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.

Authors:  Leena Abdulaziz; Esraa Elhadi; Ejlal A Abdallah; Fadlalbaseer A Alnoor; Bashir A Yousef
Journal:  J Exp Pharmacol       Date:  2022-03-08

Review 7.  Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.

Authors:  Gamal El-Din A Abuo-Rahma; Mamdouh F A Mohamed; Tarek S Ibrahim; Mai E Shoman; Ebtihal Samir; Rehab M Abd El-Baky
Journal:  RSC Adv       Date:  2020-07-17       Impact factor: 4.036

Review 8.  BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection.

Authors:  Darlene Vigil; Nikifor K Konstantinov; Marc Barry; Antonia M Harford; Karen S Servilla; Young Ho Kim; Yijuan Sun; Kavitha Ganta; Antonios H Tzamaloukas
Journal:  World J Transplant       Date:  2016-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.